Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price objective trimmed by Barclays from $13.00 to $8.00 in a research note issued to investors on Tuesday morning, The Fly reports. CHRS has been the subject of a number of other research reports. HC Wainwright decreased their price objective on shares of Coherus BioSciences from $26.00 […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price objective trimmed by Maxim Group from $15.00 to $12.00 in a report issued on Friday, The Fly reports. A number of other analysts have also recently issued reports on the company. StockNews.com began coverage on Coherus BioSciences in a report on Thursday, March 16th. They set […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price target lowered by Maxim Group from $15.00 to $12.00 in a report released on Friday morning, The Fly reports. A number of other equities research analysts also recently weighed in on the stock. UBS Group upgraded shares of Coherus BioSciences from a neutral rating to a […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) and MeiraGTx (NASDAQ:MGTX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Valuation & Earnings This table compares Coherus BioSciences and MeiraGTx’s […]